Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).

Heidelberg announced a $1 billion deal with Huadong focused on developing ADCs in Asia

Sotio Biotech

9/4/2022 | 3 minutes to read

Print
Copy link

PARTNERING

Heidelberg Pharma and Huadong Medicine announced strategic partnership on ADCs

Heidelberg Pharma and Huadong Medicine announced that the companies have entered into a strategic partnership with the signing of an exclusive licensing agreement as well as an investment agreement. The agreements were concluded with wholly owned subsidiaries of Huadong, one of the leading pharmaceutical companies in China with a focus on oncology and ADC research, development, and commercialization. Huadong Medicine will become the second-largest shareholder in oncology biotech Heidelberg Pharma as part of a partnership in which the China-based company will gain rights in Asia to at least two antibody-drug candidates. The deal includes local, ex-Japan rights to HDP-101, which targets BCMA and became Heidelberg’s first clinical program this month; and HDP-103, which targets PSMA. Both use Heidelberg’s ATAC platform. Huadong will also gain options to a program targeting CD37 and another with an undisclosed target. Heidelberg will receive $20 million up front and is eligible for $910 million in milestones, plus royalties; Huadong will receive a 35% stake as part of a rights issue and share transfer. 

OBI Pharma entered license agreement with Odeon Therapeutics for ADCs in China

OBI Pharma, and Odeon Therapeutics have entered into an exclusive license agreement whereby OBI grants rights of OBI-999, a novel antibody-drug conjugate, and OBI-833, a therapeutic cancer vaccine, targeting the tumor antigen Globo H in China, Hong Kong and Macau to Odeon. OBI will grant Odeon exclusive rights to develop, register and commercialize OBI-999 and OBI-833 for human cancer therapy in China, Hong Kong, and Macao. Odeon will issue to OBI fully paid equity equivalent to US$ 12 million upon signing. OBI is eligible for development and commercialization milestones totaling up to US$ 188 million. The company is also eligible to receive tiered double-digit royalties on net sales. Odeon will also be responsible for all development costs and all subsequent regulatory and commercialization costs of OBI-999 and OBI-833 in China, Hong Kong, and Macao.

Intellia and ONK announced collaboration on allogeneic CRISPR edited NK cell therapies

Intellia Therapeutics and ONK Therapeutics announced a licensing and collaboration agreement, which grants ONK a non-exclusive license to Intellia’s proprietary ex vivo CRISPR/Cas9-based genome editing platform and its lipid nanoparticle (LNP)-based delivery technologies to develop up to five allogeneic NK cell therapies. ONK will receive exclusive rights to certain Intellia guide RNAs (gRNAs) resulting from the collaboration for use in engineering those NK cell products. ONK will be responsible for preclinical and clinical development for the engineered NK cell therapies covered under the agreement. Intellia will be eligible to receive up to $184 million per product in development and commercial milestone payments, as well as up to mid-single digit royalties on potential future sales. In addition, the agreement grants Intellia options to co-develop and co-commercialize up to two products worldwide with rights to lead commercialization in the US ONK retains lead commercialization rights ex-US.

ImmunoGen announced license agreement of its camptothecin ADC platform with Lilly

Immunogen announced a global, multi-year definitive licensing agreement whereby it granted Lilly exclusive rights to research, develop, and commercialize ADCs directed to targets selected by Lilly based on ImmunoGen's novel camptothecin technology. ImmunoGen retains full rights to the camptothecin platform for all targets not covered by the Lilly license. Lilly will pay ImmunoGen an upfront payment of $13 million, reflecting initial targets selected by Lilly. Lilly may select a pre-specified number of additional targets, with ImmunoGen eligible to receive an additional $32.5 million in exercise fees if Lilly licenses the full number of targets. ImmunoGen is eligible to receive up to $1.7 billion in potential target program exercise fees and milestone payments based on the achievement of milestones. ImmunoGen is also eligible for tiered royalties as a percentage of worldwide commercial sales by Lilly. Lilly is responsible for all costs associated with research and development.

Overview of transactions in oncology (values in m$)

Source

Partner

Product

Stage

Rights

Value

UF

MS

Heidelberg Pharma

Huadong Medicine

License to BCMA ADC HDP-101, PSMA ADC HDP-103 and option to 2 ATAC ADCs developed against cancer

Ph 1/2

Asia,ex-JP,IN

1 048

138

910

OBI Pharma

Odeon Therapeutics

License to OBI-999, ADC targeting Globo H, and OBI-833, a Globo H cancer vaccine, developed against cancer

Ph 1

CN,HK,      MC

200

12

188

MediGene

Biontech

License to TCR based immunotherapies against cancer, and option to acquire additional future TCRs

Precl

WW

NA

30

NA

ImmunoGen

Eli Lilly

License to develop cancer ADCs against undisclosed targets based on the camptothecin ADC platform

Res

WW

1 746

13

1 733

Curve Therapeutics

Merck & Co.

License to develop five oncology and neuroscience targets using mammalian cell discovery technology

Res

WW

1 700

NA

NA

Remix Therapeutics

J&J

License to develop therapies against targets in oncology immunology using REMaster discovery platform

Res

WW

1 045

45

1 000

Mersana Therapeutics

J&J

License to develop ADCs against three targets using Dolasynthen platform against cancer indications

Res

WW

1 040

40

1 000

Intellia Therapeutics

ONK Therapeutics

License to develop up to 5 NK cell therapies using CRISPR/Cas9 based genome editing platform and LNP tech

Res

WW

920

NA

NA

Synaffix

MacroGenics

License to combine GlycoConnect, HydraSpace and toxSYN technologies with antibody platforms

Res

WW

586

NA

NA

Plexium

Amgen

License to develop new protein degradation therapies focused on two oncology programs

Res

WW

500

NA

NA

NASDAQ Initial Public Offerings (IPOs) in oncology

Company

Ticker

Lead product

Technology

Stage

Amount m$

Price $

Arcellx

ACLX

iMMagine

CART

Autologous CAR-T targeting BCMA against multiple myeloma

Phase 1

123.8

15

TC Biopharm

TCBP

OmnImmune

Unmodified allogeneic gamma delta T cell therapy against AML

Phase 1

17.5

4

Nuvectis Pharma

NVCT

NXP800

Oral small molecule HSF1-pathway inhibitor against ovarian cancer

Phase 1

16.0

5

Share on social networks

Share on social networks

Print

Copy link